Afasevikumab

INN name:	Afasevikumab
Lab codes:	MCAF-5352A, MCAF5352A, NI-1401, RG-7624, RG7624, RO5553110
Trade name:	Not yet assigned
Name:	immunoglobulin G1-kappa, anti-[Homo sapiens IL17A (interleukin 17A, IL-17A) and Homo sapiens IL17F (interleukin 17F, IL-17F)], Homo sapiens monoclonal antibody;
	gamma1 heavy chain (1-453) [Homo sapiens VH (IGHV3-9*01 (96.00%) -(IGHD)-IGHJ2*01) [8.8.16] (1-123) -IGHG1*03, G1m3 (CH1 (124-221), hinge (222-236), CH2(237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-215')-disulfide with kappa light chain (1'-215') [Homo sapiens V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ4*01) [6.3.10] (1'-108') -IGKC*01, Km3 (109'-215')]; dimer (232- 232'':235-235'')-bisdisulfide
Sequence: Heavy chain	EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWSS GGIGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDIGGFGEFYWNFGL WGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKT HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP VLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (453 amino acids)
Light chain	EIVLTQSPATLSLSPGERATLSCRASQSVRSYLAWYQQKPGQAPRLLIYDASNRATGI PARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPATFGGGTKVEIKRTVAAPSV FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (215 amino acids)
CAS Registry Number:	1589503-30-9
Originator:	NovImmune SA
Developer:	Genentech
Class:	Anti-inflammatories; Monoclonal antibodies
Mechanism of Action:	Interleukin 17 receptor antagonists
WHO ATC code:	M01 (Antiinflammatory and Antirheumatic Products)
EPhMRA code:	M1 (Anti-Inflammatory and Anti-Rheumatic Products)
FDA approval:	Not yet approved
Clinical Trials: Indication Phase Status A Study of MCAF5352A in Healthy Volunteers Phase 1 Completed Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers Phase 1 Completed The drug appears to be discontinued for Autoimmune disorders.
Product Patent Expiry: Please contact us for product patent details.
Recent activities on the drug: